HRP20190186T4 - Nove formulacije (trimetoksifenilamino)pirimidinila - Google Patents

Nove formulacije (trimetoksifenilamino)pirimidinila Download PDF

Info

Publication number
HRP20190186T4
HRP20190186T4 HRP20190186TT HRP20190186T HRP20190186T4 HR P20190186 T4 HRP20190186 T4 HR P20190186T4 HR P20190186T T HRP20190186T T HR P20190186TT HR P20190186 T HRP20190186 T HR P20190186T HR P20190186 T4 HRP20190186 T4 HR P20190186T4
Authority
HR
Croatia
Prior art keywords
formula
compound
formulation
pharmaceutical composition
composition according
Prior art date
Application number
HRP20190186TT
Other languages
English (en)
Croatian (hr)
Inventor
Farhan Abdul Karim Alhusban
Ian Paul Gabbott
Bindhumadhavan GURURAJAN
Dawn SIEVWRIGHT
David Bradley Brook Simpson
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46875902&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20190186(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Publication of HRP20190186T1 publication Critical patent/HRP20190186T1/hr
Publication of HRP20190186T4 publication Critical patent/HRP20190186T4/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HRP20190186TT 2011-07-28 2012-07-26 Nove formulacije (trimetoksifenilamino)pirimidinila HRP20190186T4 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161512621P 2011-07-28 2011-07-28
EP12759802.7A EP2736487B2 (en) 2011-07-28 2012-07-26 New (trimethoxyphenylamino)pyrimidinyl formulations
PCT/GB2012/051791 WO2013014454A1 (en) 2011-07-28 2012-07-26 New (trimethoxyphenylamino)pyrimidinyl formulations

Publications (2)

Publication Number Publication Date
HRP20190186T1 HRP20190186T1 (hr) 2019-03-22
HRP20190186T4 true HRP20190186T4 (hr) 2024-12-20

Family

ID=46875902

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190186TT HRP20190186T4 (hr) 2011-07-28 2012-07-26 Nove formulacije (trimetoksifenilamino)pirimidinila

Country Status (27)

Country Link
US (2) US8771648B2 (sr)
EP (1) EP2736487B2 (sr)
JP (1) JP6019116B2 (sr)
KR (2) KR102090440B1 (sr)
CN (1) CN103826610B (sr)
AR (1) AR087371A1 (sr)
AU (1) AU2012288632B2 (sr)
BR (1) BR112014001999B1 (sr)
CA (1) CA2843138C (sr)
CY (1) CY1122596T1 (sr)
DK (1) DK2736487T4 (sr)
EA (1) EA028432B1 (sr)
ES (1) ES2710423T5 (sr)
FI (1) FI2736487T4 (sr)
HR (1) HRP20190186T4 (sr)
HU (1) HUE042611T2 (sr)
LT (1) LT2736487T (sr)
MX (1) MX339685B (sr)
PL (1) PL2736487T5 (sr)
PT (1) PT2736487T (sr)
RS (1) RS58433B2 (sr)
SI (1) SI2736487T2 (sr)
SM (1) SMT201900071T1 (sr)
TR (1) TR201901792T4 (sr)
TW (1) TW201311251A (sr)
UY (1) UY34223A (sr)
WO (1) WO2013014454A1 (sr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE540041T1 (de) * 2006-11-21 2012-01-15 Rigel Pharmaceuticals Inc Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
HRP20190186T4 (hr) 2011-07-28 2024-12-20 Rigel Pharmaceuticals, Inc. Nove formulacije (trimetoksifenilamino)pirimidinila
PL3283551T3 (pl) 2015-04-02 2021-04-06 Stora Enso Oyj Kompozycja aktywowanej ligniny, sposób jej wytwarzania oraz jej zastosowanie
WO2016172053A1 (en) 2015-04-24 2016-10-27 Rigel Pharmaceuticals, Inc. Methods of treating ibrutinib-resistant disease
SE542795C2 (en) 2018-10-08 2020-07-07 Stora Enso Oyj Process for preparing a resin
DK4178548T3 (da) * 2020-07-07 2024-08-19 Celgene Corp Farmaceutiske sammensætninger omfattende (S)-4-(4-(4-(((2-(2,6-DIOXOPIPERIDIN-3-YL)-1-OXOISOINDOLIN-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-FLUORBENZONITRIL
WO2022017864A1 (en) * 2020-07-24 2022-01-27 Dsm Ip Assets B.V. New fast dissolvable tablets

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2291433T3 (es) 2002-03-04 2008-03-01 Orbus Pharma Inc. Composiciones de cefuroxima axetilo de liberacion rapida.
HRP20050089B1 (hr) 2002-07-29 2015-06-19 Rigel Pharmaceuticals Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
WO2005012294A1 (en) 2003-07-30 2005-02-10 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
ATE506953T1 (de) 2003-08-07 2011-05-15 Rigel Pharmaceuticals Inc 2,4-pyrimidindiamin-verbindungen und verwendungen als antiproliferative mittel
US20060051406A1 (en) * 2004-07-23 2006-03-09 Manjeet Parmar Formulation of insoluble small molecule therapeutics in lipid-based carriers
EP1794135A1 (en) * 2004-09-27 2007-06-13 Amgen Inc. Substituted heterocyclic compounds and methods of use
RU2361867C2 (ru) 2004-11-23 2009-07-20 Донг Вха Фармасьютикал. Инд. Ко., Лтд. Диметансульфонат n-гидрокси-4{5-[4-(5-изопропил-2-метил-1, 3-тиазол-4-ил)фенокси]пентокси}бензамидина
AU2006206458B2 (en) * 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US8227455B2 (en) 2005-04-18 2012-07-24 Rigel Pharmaceuticals, Inc. Methods of treating cell proliferative disorders
CA2631875A1 (en) * 2005-12-06 2007-10-04 Rigel Pharmaceuticals, Inc. Formulation of insoluble small molecule therapeutics in lipid-based carriers
US7659280B2 (en) * 2006-02-17 2010-02-09 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
US20090048214A1 (en) * 2006-11-15 2009-02-19 Rigel Pharmaceuticals, Inc Methods for Treating Renal Tumors Using 2, 4-Pyrimidinediamine Drug and Prodrug Compounds
ATE540041T1 (de) * 2006-11-21 2012-01-15 Rigel Pharmaceuticals Inc Prodrug-salze von 2,4-pyrimidindiaminverbindungen und anwendungen davon
WO2009003136A1 (en) * 2007-06-26 2008-12-31 Rigel Pharmaceuticals, Inc. Substituted pyrimidine-2, 4 -diamines for treating cell proliferative disorders
US20090088371A1 (en) * 2007-08-28 2009-04-02 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
UA102825C2 (ru) * 2007-11-07 2013-08-27 Райджел Фармасьютикалз, Инк. Фармацевтическая композиция, полученная влажным гранулированием с использованием вещества, которое связывает воду
MX2010009159A (es) 2008-02-22 2010-09-14 Rigel Pharmaceuticals Inc Uso de 2,4-pirimidindiaminas para el tratamiento de aterosclerosis.
UA108077C2 (xx) * 2009-07-02 2015-03-25 Синтез динатрієвої солі n4-(2,2-диметил-4-$(дигідрофосфонокси)метил]-3-оксо-5-піридо$1,4]оксазин-6-іл)-5-фтор-n2-(3,4,5-триметоксифеніл)-2,4-піримідиндіаміну
EP2454265A2 (en) 2009-07-17 2012-05-23 Rigel Pharmaceuticals, Inc. Deuterated 2, 4-pyrimidinediamine compounds and prodrugs thereof and their uses
JP5681723B2 (ja) 2009-11-20 2015-03-11 ライジェル ファーマシューティカルズ, インコーポレイテッド 2,4−ピリミジンジアミン化合物およびそのプロドラッグならびにそれらの使用
CA2792278C (en) 2010-04-13 2019-05-14 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and prodrugs thereof and their uses
HRP20190186T4 (hr) 2011-07-28 2024-12-20 Rigel Pharmaceuticals, Inc. Nove formulacije (trimetoksifenilamino)pirimidinila

Also Published As

Publication number Publication date
UY34223A (es) 2013-02-28
AU2012288632B2 (en) 2017-08-17
JP6019116B2 (ja) 2016-11-02
KR20140058576A (ko) 2014-05-14
JP2014521630A (ja) 2014-08-28
HRP20190186T1 (hr) 2019-03-22
EP2736487A1 (en) 2014-06-04
US8771648B2 (en) 2014-07-08
TR201901792T4 (tr) 2019-03-21
TW201311251A (zh) 2013-03-16
SMT201900071T1 (it) 2019-02-28
DK2736487T4 (da) 2024-11-04
US20130058876A1 (en) 2013-03-07
PL2736487T5 (pl) 2025-01-27
EP2736487B1 (en) 2018-11-07
CY1122596T1 (el) 2021-01-27
ES2710423T5 (en) 2025-02-13
FI2736487T4 (fi) 2024-10-31
KR102090440B1 (ko) 2020-03-17
KR102024120B1 (ko) 2019-09-23
EP2736487B2 (en) 2024-08-28
SI2736487T2 (sl) 2025-06-30
US8951504B2 (en) 2015-02-10
CN103826610B (zh) 2017-08-04
RS58433B1 (sr) 2019-04-30
CN103826610A (zh) 2014-05-28
ES2710423T3 (es) 2019-04-25
PL2736487T3 (pl) 2019-06-28
BR112014001999B1 (pt) 2023-11-28
HK1198741A1 (en) 2015-06-05
EA028432B1 (ru) 2017-11-30
DK2736487T3 (en) 2019-03-04
MX339685B (es) 2016-06-06
RS58433B2 (sr) 2025-01-31
CA2843138A1 (en) 2013-01-31
KR20190109576A (ko) 2019-09-25
HUE042611T2 (hu) 2019-07-29
US20140271493A1 (en) 2014-09-18
WO2013014454A1 (en) 2013-01-31
MX2014001065A (es) 2014-08-01
BR112014001999A2 (pt) 2017-02-21
EA201490363A1 (ru) 2014-06-30
PT2736487T (pt) 2019-02-13
CA2843138C (en) 2020-06-02
LT2736487T (lt) 2019-02-25
AU2012288632A1 (en) 2014-02-20
AR087371A1 (es) 2014-03-19
SI2736487T1 (sl) 2019-04-30

Similar Documents

Publication Publication Date Title
HRP20190186T4 (hr) Nove formulacije (trimetoksifenilamino)pirimidinila
HRP20160179T1 (hr) Formulacije apiksabana
FI3470063T3 (fi) Lääkekoostumuksia cftr-välitteisten sairauksien hoitoon
RU2011141496A (ru) Таблетки и гранулированные порошки, содержащие 6-фтор-3-гидрокси-2-пиразинкарбоксамид
RU2017134002A (ru) Стабильные композиции тетрагидробиоптерина
HRP20210516T2 (hr) Postupak proizvodnje farmaceutskih pripravaka za liječenje bolesti koje su posredovane putem cftr
SG10201804024VA (en) Formulations of azaindole compounds
HRP20161262T1 (hr) Tablete ulipristal acetata
HRP20211423T1 (hr) Formulacije enzalutamida
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
NZ611467A (en) Rapidly dispersing granules, orally disintegrating tablets and methods
HRP20251373T1 (hr) Mikroporozni cirkonijev silikat za liječenje hiperkalijemije
TN2012000246A1 (en) Pharmaceutical compositions comprising sigma receptor ligands
JP2011525501A5 (sr)
HRP20240720T1 (hr) Farmaceutski pripravak, koji sadrži čestice fosfatnog veziva
HRP20151347T1 (hr) Nova kombinacija
HRP20191217T1 (hr) Čvrsti farmaceutski sastav citizina i postupak pripreme istog
JP2012001473A5 (sr)
TW201129386A (en) Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients
JP2012105574A5 (sr)
CN104622827A (zh) 托法替布片剂及其制备方法
PH12015501301B1 (en) A pharmaceutical composition containing candesartan cilexetil and amlodipine
HRP20201217T1 (hr) Derivati di(fenilpropanoid)glicerola za liječenje raka
RU2016106328A (ru) Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
HRP20211524T1 (hr) Sol derivata cefalosporina, kristalni kruti oblik istog i postupak za njegovu proizvodnju